BioPharmSignal logoBioPharmSignal

Biotech News

Adaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of Cure

Adaptive Biotechnologies (ADPT)Adaptive BiotechnologiesCommercial

Definition requires five years off myeloma treatment with sustained MRD negativity, assessed with technology sensitive enough to identify one myeloma cell among one million cells SEATTLE, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage

Related news

ADPTAdaptive Biotechnologies2026-09-17 12:00 EST

Adaptive Biotechnologies Announces Update to NCCN Guidelines® for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ®

ADPTAdaptive Biotechnologies2026-09-01 20:05 EST

Adaptive Biotechnologies to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

ICUSeaStar Medical2026-10-05 12:00 EST

SeaStar Medical Announces Exercise of Warrants for Approximately $3.3 Million Gross Proceeds

IARTIntegra LifeSciences2026-10-02 12:00 EST

Integra LifeSciences Announces Launch of $600 Million Senior Secured Term Loan B

CVRXCVRx2026-09-21 20:08 EST

CVRx Appoints John Landry as Chief Financial Officer

CVRXCVRx2026-08-25 12:00 EST

CVRx Responds to Letter from Pointillist Family Office

HYPRHyperfine2026-08-26 12:15 EST

Hyperfine Builds Momentum in Year One of Neurology Office Launch with NEURO PMR Publication and More Than 3,000 Scans

PAVMPAVmed2026-08-05 12:46 EST

Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA Test

PAVMPAVmed2026-08-04 12:30 EST

Lucid Diagnostics to Participate in Upcoming Investor Conferences

VTAKCatheter Precision2026-08-27 12:00 EST

Catheter Precision Achieves Major Commercial Milestones with Cardinal Health, Johns Hopkins and the placement of the First VIVO System in Germany

View all latest news

Adaptive Biotechnologies

Adaptive Immune-System Platform Adaptive Biotechnologies develops clinical products by decoding the genetics of the adaptive immune system. Its proprietary platform measures immune-receptor sequences at scale to support disease monitoring, drug development and the discovery of immune-based therapeutics. Minimal Residual Disease The...

Recent company news

ADPTAdaptive Biotechnologies2026-09-25 12:03 EST

Adaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of Cure

ADPTAdaptive Biotechnologies2026-09-17 12:00 EST

Adaptive Biotechnologies Announces Update to NCCN Guidelines® for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ®

ADPTAdaptive Biotechnologies2026-09-01 20:05 EST

Adaptive Biotechnologies to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

ADPTAdaptive Biotechnologies2026-07-29 20:05 EST

Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results

ADPTAdaptive Biotechnologies2026-07-09 20:05 EST

Adaptive Biotechnologies to Report Second Quarter 2026 Financial Results on July 29, 2026

Stock data

Close
27.37 USD
Market cap
2.42B USD
Exchange
NASDAQ
Sector
MedTech
Location
United States